We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen-Sandoz Biosimilar Case Draws Support from Both Sides
Amgen-Sandoz Biosimilar Case Draws Support from Both Sides
GPhA Wednesday threw its weight behind Sandoz in closely watched litigation between Amgen and the French drugmaker, saying the U.S. district court in northern California was correct in denying Amgen’s request for a preliminary injunction to keep Sandoz’ biosimilar of Neupogen off the market.